RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development

Opaganib awarded a further $1.7 million in U.S. Government funding for development as a medical countermeasure for gastrointestinal acute radiation syndrome...

Related Keywords

United Kingdom ,Israel ,United States ,American ,Redhill Biopharma ,Dror Ben Asher ,Adi Frish ,Small Business Innovation Research ,Nasdaq ,International Journal Of Molecular Sciences ,Apogee Biotechnology Corporation ,Product Development Pipeline ,Redhill Biopharma Ltd ,Company Annual Report On Form ,Company Expanded Access Program ,Corporate Business Development ,Exchange Commission ,Nuclear Countermeasures Program ,Animal Rule ,International Journal ,Molecular Sciences ,Radiation Toxicity ,Homeland Security ,Acute Radiation Syndrome ,Orphan Drug ,Hill Biopharma ,Private Securities Litigation Reform Act ,Development Pipeline ,Expanded Access Program ,Annual Report ,Sphingosine Kinase ,Hematopoietic Stem Cells ,Improving Their Metabolic ,